1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

G.V Long,J.C Hassel,M.K Mujika Eizmendi,M Hernberg,D Schadendorf,S Rodriguez,P.A Ascierto,B Ratto,F.A Medina Soto,H.A Tawbi,G Cinat,P.T Wang,J Mackiewicz,V.G Atkinson,S Dolfi,F.S Hodi,S Prey,M Maio,E.J Lipson

doi:10.1016/j.annonc.2023.09.2237

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

G.V Long, J.C Hassel + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.2237

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

#Nivolumab #Unresectable Melanoma + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.